Drugs that treat rare diseases have transformed an industry struggling for growth


Work to combat these rare illnesses, while expensive in an age of austerity, is challenging the traditional model of the pharmaceutical industry. The knowhow required to fight orphan diseases has been at the forefront of efforts to identify, develop and monitor treatment of far more common maladies. You can find the full text of the article, published in Financial times here.

Latest News